Irinotecan hydrochloride (anhydrous) is a hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, that is ~1000 times more active. Among its listed roles, it functions as a EC 5.99.1.2 (DNA topoisomerase) inhibitor, an antineoplastic agent, an apoptosis inducer and a prodrug. It includes a irinotecan. It is grouped under the following drug class(es): Antineoplastic agents, Cytotoxics and Topoisomerase inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Camptosar, CPT-11 and Irinotecan HCl. Its PubChem CID is 74990.
Irinotecan hydrochloride
| CAS No | 100286-90-6 |
|---|---|
| Molecular Formula | C33H39ClN4O6 |
| Molecular Weight | 623.14 g/mol |
| Synonyms | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Irinotecan hydrochloride (anhydrous) is a hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid.
The listed CAS number is 100286-90-6.
The listed molecular formula is C33H39ClN4O6.
The listed molecular weight is 623.14 g/mol.
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride.
The source lists Camptosar, CPT-11 and Irinotecan HCl.